Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.8500 -0.0250 (-2.86%)

Streaming Delayed Price Updated: 1:29 PM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Volume	63,238
Open	0.8733
Bid (Size)	0.8345 (100)
Ask (Size)	0.8600 (800)
Prev. Close	0.8750
Today's Range	0.7812 - 0.8749
52wk Range	0.5480 - 2.790
Shares Outstanding	5,979,292
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗

February 18, 2026

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Via Stocktwits

The market is filled with gapping stocks in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Performance

YTD	-0.4%	-0.4%
1 Month	+3.7%	+3.7%
3 Month	-32.0%	-32.0%
6 Month	-46.9%	-46.9%
1 Year	-66.3%	-66.3%

More News

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

February 18, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

February 12, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

February 04, 2026

From Aprea Therapeutics

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

January 30, 2026

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

January 30, 2026

Via Chartmill

In today's session, these stocks are experiencing unusual volume. ↗

January 30, 2026

Via Chartmill

Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗

January 30, 2026

Via Chartmill

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

January 29, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 29, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

December 18, 2025

From Aprea Therapeutics

Via GlobeNewswire

Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now

December 10, 2025

Via AB Newswire

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 09, 2025

From Aprea Therapeutics

Via GlobeNewswire

Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.

November 20, 2025

Via AB Newswire

Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target

November 18, 2025

Via AB Newswire

Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era

November 12, 2025

Via AB Newswire

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

November 12, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside

November 03, 2025

Via AB Newswire

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

October 24, 2025

From Aprea Therapeutics

Via GlobeNewswire

Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside

October 17, 2025

Via AB Newswire

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

October 15, 2025

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From Aprea Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?

Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?

The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market

What is the current price of Aprea Therapeutics, Inc. - Common Stock?

The current price of Aprea Therapeutics, Inc. - Common Stock is 0.8500

When was Aprea Therapeutics, Inc. - Common Stock last traded?

The last trade of Aprea Therapeutics, Inc. - Common Stock was at 02/26/26 01:29 PM ET

What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?

The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 5.08M

How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?

Aprea Therapeutics, Inc. - Common Stock has 5M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.